Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Akebia Therapeutics revenue
Akebia Therapeutics's revenue is $160.2 million.
What is Akebia Therapeutics's revenue?
- Akebia Therapeutics's revenue growth from 2016 to 2024 is 10,335.18%.
- Akebia Therapeutics has 324 employees, and the revenue per employee ratio is $494,382.
- Akebia Therapeutics's peak quarterly revenue was $126.4M in 2022(q2).
- Akebia Therapeutics peak revenue was $335.0M in 2019.
- Akebia Therapeutics annual revenue for 2023 was 194.6M, -33.46% growth from 2022.
- Akebia Therapeutics annual revenue for 2024 was 160.2M, -17.7% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Akebia Therapeutics historical revenue
Akebia Therapeutics's peak revenue was $335.0M in 2019. The peak quarterly revenue was $126.4M in 2022(q2).
Akebia Therapeutics's revenue increased from $1.5m in 2016 to $160.2M currently. That's a 10,335.18% change in annual revenue.
Akebia Therapeutics annual revenue
Akebia Therapeutics annual revenue over time
| Fiscal year / year | Akebia Therapeutics revenue |
|---|---|
| 2016 | $1.5M |
| 2017 | $181.2M |
| 2018 | $207.7M |
| 2019 | $335.0M |
| 2020 | $295.3M |
| 2021 | $213.6M |
| 2022 | $292.5M |
| 2023 | $194.6M |
| 2024 | $160.2M |
How accurately did Akebia Therapeutics' revenue projections match actual performance?
Akebia Therapeutics annual growth
Akebia Therapeutics saw the greatest revenue growth in 2017, when revenue increased by 11,706.32%.
Akebia Therapeutics had the lowest revenue growth in 2021, when revenue changed by -27.68%.
Akebia Therapeutics annual growth rate over time
| Year | Akebia Therapeutics growth |
|---|---|
| 2017 | 11706%↑ |
| 2018 | 15%↑ |
| 2019 | 61%↑ |
| 2020 | -12%↓ |
| 2021 | -28%↓ |
| 2022 | 37%↑ |
| 2023 | -33%↓ |
| 2024 | -18%↓ |
Akebia Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Akebia Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | - | - | $1.5M |
| 2017 | $20.9M | $28.5M | $41.3M | $90.6M |
| 2018 | $45.9M | $48.8M | $53.2M | $59.9M |
| 2019 | $72.7M | $100.8M | $92.0M | $69.6M |
| 2020 | $88.5M | $90.1M | $60.0M | $56.7M |
| 2021 | $52.3M | $52.9M | $48.8M | $59.6M |
| 2022 | $61.7M | $126.4M | $48.7M | $55.8M |
| 2023 | $40.0M | $56.4M | $42.0M | $56.2M |
| 2024 | $32.6M | $43.6M | $37.4M | $46.5M |
Akebia Therapeutics jobs nearby
Do you work at Akebia Therapeutics?
Did Akebia Therapeutics meet its revenue projections?
Akebia Therapeutics financial information
| CEO | John P. Butler |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 324 |
| Date Founded | 2007 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $160.2M |
| Net Income | -$92,562,000 |
| Gross Proft | $97.0M (2024) |
| PE Ratio | -4.71 |
| Tax Rate | 0.1% |
| Market Capitalization | $327.2M |
| Total Assets | $356,054,000 |
| Ticker | AKBA |
Akebia Therapeutics jobs you might like
Akebia Therapeutics financing
Akebia Therapeutics received early financing of $1.1M on 2007-09-17.
| Series | Round size | Date |
|---|---|---|
| Seed | $1.1M | 09/2007 |
| Series A | $25M | 07/2009 |
| Series B | $22M | 04/2011 |
| Series C | $41M | 06/2013 |
| Post Ipo Debt | $100M | 11/2019 |
| Post Ipo Equity | $151.8M | 05/2020 |
Akebia Therapeutics investors
| Investors | Security type |
|---|---|
| CincyTech LLC | Seed |
| Novartis Venture Fund | Series A |
| Athenian Venture Partners | Series A |
| Triathlon Medical Ventures | Series A |
| Kearny Venture Partners | Series A |
| Venture Investors LLC | Series A |
| Orchard Venture Partners | Series A |
| Novartis Venture Fund | Series B |
| Athenian Venture Partners | Series B |
| Triathlon Medical Ventures | Series B |
| Kearny Venture Partners | Series B |
| Venture Investors LLC | Series B |
| AgeChem Venture Fund | Series B |
| Orchard Venture Partners | Series B |
| Novartis Venture Fund | Series C |
| Athenian Venture Partners | Series C |
| Novo Holdings A | Series C |
| SATTER INVESTMENT MANAGEMENT | Series C |
| Kearny Venture Partners | Series C |
| Triathlon Medical Ventures | Series C |
| Venture Investors LLC | Series C |
| AgeChem Venture Fund | Series C |
| Orchard Venture Partners | Series C |
| PHARMAKON ADVISORS LP | Post Ipo Debt |
Akebia Therapeutics competitors
Akebia Therapeutics's top competitor, Abraxis BioScience, earned an annual revenue of $359.0M.
Akebia Therapeutics's smallest competitor is Argos Therapeutics with revenue of $1.9M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Abraxis BioScience | - | $359.0M | 885 | - |
| Argos Therapeutics | - | $1.9M | 76 | - |
| ImmunoGen | - | $108.8M | 75 | - |
| Tetraphase Pharmaceuticals | - | $7.4M | 67 | - |
| Karyopharm | - | $145.2M | 442 | - |
| Turning Point Therapeutics | - | $25.0M | 142 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Akebia Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Akebia Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Akebia Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Akebia Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Akebia Therapeutics. The data presented on this page does not represent the view of Akebia Therapeutics and its employees or that of Zippia.
Akebia Therapeutics may also be known as or be related to AKEBIA THERAPEUTICS INC., Akebia Therapeutics, Akebia Therapeutics Inc, Akebia Therapeutics Inc. and Akebia Therapeutics, Inc.